Catalyst Pharmaceuticals Files 8-K on Director, Officer, and Compensation Changes

Ticker: CPRX · Form: 8-K · Filed: 2025-05-23T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, executive-compensation, board-of-directors

Related Tickers: CPRX

TL;DR

Catalyst Pharma 8-K: Board shakeup, exec pay changes, and shareholder votes filed May 20.

AI Summary

Catalyst Pharmaceuticals, Inc. announced on May 20, 2025, changes in its board of directors and executive compensation arrangements. The company also reported on matters submitted for a vote by its security holders. Specific details regarding the director changes, officer appointments, and compensation adjustments were filed in this 8-K report.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in leadership and compensation can introduce uncertainty, but the filing itself is a routine disclosure.

Key Players & Entities

FAQ

What specific changes were made to the board of directors?

The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not detail the specific individuals or changes within this summary.

What are the key details of the compensatory arrangements mentioned?

The filing notes 'Compensatory Arrangements of Certain Officers' as an item of information, but the specific details of these arrangements are not provided in the summary text.

What matters were submitted to a vote of security holders?

The filing states 'Submission of Matters to a Vote of Security Holders' as an item of information, but the nature of these matters is not specified in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on May 20, 2025.

What is Catalyst Pharmaceuticals, Inc.'s standard industrial classification?

Catalyst Pharmaceuticals, Inc.'s standard industrial classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.

From the Filing

0001193125-25-125872.txt : 20250523 0001193125-25-125872.hdr.sgml : 20250523 20250523163014 ACCESSION NUMBER: 0001193125-25-125872 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250520 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250523 DATE AS OF CHANGE: 20250523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 25982851 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d940123d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2025-05-20 2025-05-20     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 20, 2025     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle   Suite 801   Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers At the Company’s 2025 Annual Meeting of Stockholders held on May 20, 2025 (“ Annual Meeting

View on Read The Filing